Longeveron (LGVN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

LGVN Longeveron

Watchlist

1.890
+0.020+1.07%

Close Nov 22 16:00 ET

1.910
+0.020+1.06%

Post 20:01 ET

28.04MMarket Cap-336P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate
Yahoo FinanceNov 15 06:43 ET
Express News | Watching Longeveron; Zacks Small-Cap Research Sets $9.50 Price Valuation
BenzingaNov 13 10:00 ET
Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript Summary
moomoo AINov 12 22:59 ET · Conference Call
Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript
Earnings Call TranscriptsNov 12 22:37 ET
Longeveron | 10-Q: Q3 2024 Earnings Report
SECNov 12 16:46 ET · Announcements
Longeveron 3Q Loss/Shr 34c >LGVN
Dow JonesNov 12 16:39 ET

Comments

In Faith We Trust

Nov 20 11:01

$Longeveron (LGVN.US)$ Fxxx stock. loose so much

103673643

Nov 18 17:43

$Longeveron (LGVN.US)$
Longeveron Reports Positive FDA Type C Meeting on BLA Pathway for Lomecel-B in HLHS
The Phase 2B trial for the CLEAR MIND study, which evaluates Lomecel-B for mild Alzheimer's disease, is anticipated to start following a meeting with the FDA before the end of 2024. This meeting aims to outline the future clinical and regulatory strategy for Lomecel-B, based on the positive results from the Phase 2A trial. Specific timelines for initiating the Phase 2B trial will depend on t...